<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00308997</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH073673-01</org_study_id>
    <secondary_id>R01MH073673-01</secondary_id>
    <secondary_id>DATR A5-ETPD</secondary_id>
    <nct_id>NCT00308997</nct_id>
  </id_info>
  <brief_title>Transcranial Magnetic Stimulation for &quot;Voices&quot;</brief_title>
  <official_title>Transcranial Magnetic Stimulation Guided by Neuroimaging for Patients With Persistent &quot;Voices&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the efficacy of MRI-guided transcranial magnetic stimulation
      (TMS)in reducing &quot;voices&quot; and other symptoms experienced by people with schizophrenia and
      schizoaffective disorder. In addition, the study will determine duration of improvement
      obtained during the course of trial participation via on-going monthly contact with study
      participants for up to 1 year after the trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Schizophrenia is a severely disabling brain disorder that affects about 1% of the United
      States population. Approximately 50 to 80% of people with schizophrenia experience &quot;voices,&quot;
      also known as auditory hallucinations. These hallucinations consist of spoken speech, which
      sometimes replicates the speaking voice of a familiar person, and sometimes reflects a
      speaking voice that is not known but becomes highly recognizable. The phrases and sentences
      expressed by &quot;voices&quot; are often highly disruptive, and may comment, cajole, criticize, and,
      in some cases, command the patient. They are often but not invariably distressing, and can
      disrupt one's ability to interact with others, work, study, and sleep. In about 25% of cases,
      medication treatment is either completely ineffective or only partially effective in
      relieving &quot;voices.&quot; Effective treatment alternatives are needed to improve this troubling and
      often disabling symptom.

      Recent studies have suggested that auditory hallucinations arise from parts of the brain that
      are ordinarily involved in perceiving actual spoken speech. Low frequency repetitive
      transcranial magnetic stimulation (rTMS), a technique that uses an electromagnet to induce
      reductions in cortical brain activity, may therefore be effective in quieting auditory
      hallucinations. The potential usefulness of this approach has been demonstrated by previous
      studies conducted at our medical center. This new study uses magnetic resonance imaging (MRI)
      to locate two areas of the brain involved in speech perception. These areas are in Wernicke's
      area in the left superior temporal gyrus, and in the right hemisphere in an analogous site in
      the superior temporal gyrus. Repetitive TMS is specifically positioned to reduce cortical
      excitability or reactivity at these two brain regions.

      Participants in this double blind study will be randomly assigned to receive either real
      rTMS, or placebo stimulation, which feels similar to real rTMS but does not produce direct
      brain effects. Depending on group assignment, participation may last 4 to 8 weeks. Over the
      first 2 weeks, all participants will undergo two sequences of rTMS, each consisting of five
      16-minute sessions. One sequence is directed to left Wernicke's area and the other sequence
      is directed to the right-sided equivalent area. During the third week, participants will
      receive five additional sessions to the left or right site that appeared to produce greater
      clinical improvement. All participants will then be informed as to whether they received real
      or placebo stimulation. Participants who received real stimulation will be offered 5
      additional stimulation sessions at the brain site that achieved the best response.
      Participants who received placebo stimulation will be offered real stimulation for up to
      twenty sessions over 4 weeks using the same schedule described above. Assessments of severity
      of hallucinations and other clinical symptoms will be conducted after every fifth rTMS
      session by a clinician who does not know whether the participant is receiving real or placebo
      stimulation.

      Neuropsychological testing will also be done before, during, and after the trial. Our
      previous trial demonstrated some improvement in verbal processing with no significant
      impairments in terms of memory, language or cognitive function. However, insofar as this
      trial involves a greater total &quot;dose&quot; of rTMS, careful monitoring of these functions is
      conducted throughout the trial.

      In addition, the study will determine the degree to which improvement obtained during the
      course of trial is sustained over the ensuing months. This is accomplished via on-going
      monthly contact with study participants for up to 1 year after the last rTMS stimulation
      session.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hallucination Change Score - Right (HCS-right)</measure>
    <time_frame>After 5 sessions of rTMS</time_frame>
    <description>HCS score for participants assessed after 5 sessions, 16 minutes per session, who received either rTMS or sham stimulation delivered to the right superior temporal gyrus.
HCS was anchored at 0 (corresponding to no AVHs), 10 (no change in hallucination severity) and 20 (AVHs twice as severe as baseline). Lower scores correspond to greater improvement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hallucination Change Score - Left (HCS-left)</measure>
    <time_frame>After 5 sessions of rTMS</time_frame>
    <description>HCS score for participants assessed after 5 sessions, 16 minutes per session, who received either rTMS or sham stimulation delivered to the left superior temporal gyrus.
HCS was anchored at 0 (corresponding to no AVHs), 10 (no change in hallucination severity) and 20 (AVHs twice as severe as baseline). Lower scores correspond to greater improvement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hallucination Change Score (HCS)</measure>
    <time_frame>After 15 sessions of rTMS</time_frame>
    <description>HCS score assessed after 15 sessions, 16 minutes per session, delivered to both right superior temporal and left superior temporal gyrus sites using either rTMS or sham stimulation. For patients dropping out of the trial prematurely, last-observation-carried-forward data were used for this outcome variable.
HCS was anchored at 0 (corresponding to no AVHs), 10 (no change in hallucination severity) and 20 (AVHs twice as severe as baseline). Lower scores correspond to greater improvement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hallucination Frequency</measure>
    <time_frame>After 15 sessions of rTMS</time_frame>
    <description>AHRS frequency scale score assessed after 15 sessions, 16 minutes per session, of both right superior temporal and left superior temporal gyrus sites using either rTMS or sham stimulation (3 weeks). For patients dropping out of the trial prematurely, last-observation-carried-forward data were used for this outcome variable. The hallucination frequency range is from 0-9. The scores reported are difference scores, and an improvement is a higher score.
Hallucination frequency is one of the variables incorporated into the AHRS (Auditory Hallucinations Rating Scale). The score is measured as change relative to baseline (i.e., baseline minus endpoint). Larger (positive) scores correspond to greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Auditory Hall Rating Scale (AHRS) Score</measure>
    <time_frame>After 15 sessions of rTMS</time_frame>
    <description>Total AHRS score assessed after 15 sessions, 16 minutes per session, of both right superior temporal and left superior temporal gyrus sites using either rTMS or sham stimulation (3 weeks). For patients dropping out of the trial prematurely, last-observation-carried-forward data were used for this outcome variable. The score range is from 0-42. This is reported as a difference score and a higher score is an improvement.
Total AHRS score is measured as change relative baseline (i.e., baseline minus endpoint). Larger (positive) scores correspond to greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Improvement (CGI)Improvement</measure>
    <time_frame>After 15 sessions of rTMS</time_frame>
    <description>CGI score assessed after 15 sessions, 16 minutes per session, of both right superior temporal and left superior temporal gyrus sites using either rTMS or sham stimulation (3 weeks). For patients dropping out of the trial prematurely, last-observation-carried-forward data were used for this outcome variable. The range for this score is from 1 to 7.
Lower scores correspond to greater improvement</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Hallucinations</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active 1-hertz Repetitive Transcranial Magnetic Stimulation to Wernicke's area and right homologous area</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>sham rTMS to Wernicke's area and a right homologous area</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>1-hertz Repetitive Transcranial Magnetic Stimulation</intervention_name>
    <description>Sham stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Magstim Rapid-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active 1-Hertz Repetitive transcranial magnetic stimulation</intervention_name>
    <description>Active stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Magstim Rapid-2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Auditory hallucinations that occur at least five times per day, on average

          -  Diagnosis of schizophrenia or schizoaffective disorder

        Exclusion Criteria:

          -  Pregnant

          -  History of seizure that is not drug-induced or secondary to alcohol withdrawal

          -  Drug or alcohol abuse within 6 weeks of study entry (prior history of drug or alcohol
             abuse is not an exclusion)

          -  Changes in antipsychotic drug dosages within 4 weeks of study entry (patients do not
             need to be on antipsychotic medication to be included)

          -  Current significant untreated or unstable medical illness (e.g., poorly controlled
             diabetes mellitus, severe hypertension, unstable cardiac arrhythmia)

          -  Inability to understand the nature of the study due to severe psychotic
             disorganization, mental retardation, etc.

          -  Significant neurological condition (e.g., traumatic brain injury, multiple sclerosis)

          -  Factors that would preclude an MRI scan (e.g., severe obesity, claustrophobia, certain
             surgical implants with metallic components, metal shavings in the eye acquired while
             working as machinist)

          -  Cardiac pacemaker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph E. Hoffman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University School of Medicine, Department of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale Psychiatric Research</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://info.med.yale.edu/psych/clinics/rTMS.html</url>
    <description>Click here for the Yale University website with information about this study</description>
  </link>
  <reference>
    <citation>Hoffman RE, Gueorguieva R, Hawkins KA, Varanko M, Boutros NN, Wu YT, Carroll K, Krystal JH. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biol Psychiatry. 2005 Jul 15;58(2):97-104.</citation>
    <PMID>15936729</PMID>
  </reference>
  <reference>
    <citation>Hoffman RE, Boutros NN, Hu S, Berman RM, Krystal JH, Charney DS. Transcranial magnetic stimulation and auditory hallucinations in schizophrenia. Lancet. 2000 Mar 25;355(9209):1073-5.</citation>
    <PMID>10744097</PMID>
  </reference>
  <reference>
    <citation>Hoffman RE, Cavus I. Slow transcranial magnetic stimulation, long-term depotentiation, and brain hyperexcitability disorders. Am J Psychiatry. 2002 Jul;159(7):1093-102. Review.</citation>
    <PMID>12091184</PMID>
  </reference>
  <reference>
    <citation>Poulet E, Brunelin J, Bediou B, Bation R, Forgeard L, Dalery J, d'Amato T, Saoud M. Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia. Biol Psychiatry. 2005 Jan 15;57(2):188-91.</citation>
    <PMID>15652879</PMID>
  </reference>
  <reference>
    <citation>Chibbaro G, Daniele M, Alagona G, Di Pasquale C, Cannav√≤ M, Rapisarda V, Bella R, Pennisi G. Repetitive transcranial magnetic stimulation in schizophrenic patients reporting auditory hallucinations. Neurosci Lett. 2005 Jul 22-29;383(1-2):54-7. Epub 2005 Apr 15.</citation>
    <PMID>15936511</PMID>
  </reference>
  <reference>
    <citation>Fitzgerald PB, Benitez J, Daskalakis JZ, Brown TL, Marston NA, de Castella A, Kulkarni J. A double-blind sham-controlled trial of repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations. J Clin Psychopharmacol. 2005 Aug;25(4):358-62.</citation>
    <PMID>16012279</PMID>
  </reference>
  <reference>
    <citation>Hoffman RE, Hampson M, Wu K, Anderson AW, Gore JC, Buchanan RJ, Constable RT, Hawkins KA, Sahay N, Krystal JH. Probing the pathophysiology of auditory/verbal hallucinations by combining functional magnetic resonance imaging and transcranial magnetic stimulation. Cereb Cortex. 2007 Nov;17(11):2733-43. Epub 2007 Feb 13.</citation>
    <PMID>17298962</PMID>
  </reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2006</study_first_submitted>
  <study_first_submitted_qc>March 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2006</study_first_posted>
  <results_first_submitted>November 14, 2012</results_first_submitted>
  <results_first_submitted_qc>December 13, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 24, 2013</results_first_posted>
  <last_update_submitted>December 13, 2012</last_update_submitted>
  <last_update_submitted_qc>December 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Ralph Edward Hoffman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Auditory Hallucinations</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Schizoaffective Disorder</keyword>
  <keyword>Repetitive Transcranial Magnetic Stimulation</keyword>
  <keyword>Wernicke's Area</keyword>
  <keyword>Superior Temporal Gyrus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Hallucinations</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active Arm</title>
          <description>Active 1-hertz Repetitive Transcranial Magnetic Stimulation to Wernicke's area and right homologous area
Active 1-Hertz Repetitive transcranial magnetic stimulation : Active stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Arm</title>
          <description>sham rTMS to Wernicke's area and a right homologous area
1-hertz Repetitive Transcranial Magnetic Stimulation : Sham stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject feigned clinical data</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to tolerate intervention</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Arm</title>
          <description>Active 1-hertz Repetitive Transcranial Magnetic Stimulation to Wernicke's area and right homologous area
Active 1-Hertz Repetitive transcranial magnetic stimulation : Active stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Arm</title>
          <description>sham rTMS to Wernicke's area and a right homologous area
1-hertz Repetitive Transcranial Magnetic Stimulation : Sham stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="83"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.7" spread="11.0"/>
                    <measurement group_id="B2" value="34.0" spread="10.0"/>
                    <measurement group_id="B3" value="35.8" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hallucination Change Score - Right (HCS-right)</title>
        <description>HCS score for participants assessed after 5 sessions, 16 minutes per session, who received either rTMS or sham stimulation delivered to the right superior temporal gyrus.
HCS was anchored at 0 (corresponding to no AVHs), 10 (no change in hallucination severity) and 20 (AVHs twice as severe as baseline). Lower scores correspond to greater improvement</description>
        <time_frame>After 5 sessions of rTMS</time_frame>
        <population>Subjects who did not complete the intervention were not analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Active Arm</title>
            <description>Active 1-hertz Repetitive Transcranial Magnetic Stimulation to Wernicke's area and right homologous area
Active 1-Hertz Repetitive transcranial magnetic stimulation : Active stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>sham rTMS to Wernicke's area and a right homologous area
1-hertz Repetitive Transcranial Magnetic Stimulation : Sham stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.</description>
          </group>
        </group_list>
        <measure>
          <title>Hallucination Change Score - Right (HCS-right)</title>
          <description>HCS score for participants assessed after 5 sessions, 16 minutes per session, who received either rTMS or sham stimulation delivered to the right superior temporal gyrus.
HCS was anchored at 0 (corresponding to no AVHs), 10 (no change in hallucination severity) and 20 (AVHs twice as severe as baseline). Lower scores correspond to greater improvement</description>
          <population>Subjects who did not complete the intervention were not analyzed</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.78" spread="2.68"/>
                    <measurement group_id="O2" value="9.30" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hallucination Change Score - Left (HCS-left)</title>
        <description>HCS score for participants assessed after 5 sessions, 16 minutes per session, who received either rTMS or sham stimulation delivered to the left superior temporal gyrus.
HCS was anchored at 0 (corresponding to no AVHs), 10 (no change in hallucination severity) and 20 (AVHs twice as severe as baseline). Lower scores correspond to greater improvement</description>
        <time_frame>After 5 sessions of rTMS</time_frame>
        <population>Subjects who did not complete the intervention were not included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Active Arm</title>
            <description>Active 1-hertz Repetitive Transcranial Magnetic Stimulation to Wernicke's area and right homologous area
Active 1-Hertz Repetitive transcranial magnetic stimulation : Active stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>sham rTMS to Wernicke's area and a right homologous area
1-hertz Repetitive Transcranial Magnetic Stimulation : Sham stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.</description>
          </group>
        </group_list>
        <measure>
          <title>Hallucination Change Score - Left (HCS-left)</title>
          <description>HCS score for participants assessed after 5 sessions, 16 minutes per session, who received either rTMS or sham stimulation delivered to the left superior temporal gyrus.
HCS was anchored at 0 (corresponding to no AVHs), 10 (no change in hallucination severity) and 20 (AVHs twice as severe as baseline). Lower scores correspond to greater improvement</description>
          <population>Subjects who did not complete the intervention were not included in the analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.65" spread="2.74"/>
                    <measurement group_id="O2" value="8.50" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hallucination Change Score (HCS)</title>
        <description>HCS score assessed after 15 sessions, 16 minutes per session, delivered to both right superior temporal and left superior temporal gyrus sites using either rTMS or sham stimulation. For patients dropping out of the trial prematurely, last-observation-carried-forward data were used for this outcome variable.
HCS was anchored at 0 (corresponding to no AVHs), 10 (no change in hallucination severity) and 20 (AVHs twice as severe as baseline). Lower scores correspond to greater improvement</description>
        <time_frame>After 15 sessions of rTMS</time_frame>
        <population>Subjects who did not complete the intervention were excluded from the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Active Arm</title>
            <description>Active 1-hertz Repetitive Transcranial Magnetic Stimulation to Wernicke's area and right homologous area
Active 1-Hertz Repetitive transcranial magnetic stimulation : Active stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>sham rTMS to Wernicke's area and a right homologous area
1-hertz Repetitive Transcranial Magnetic Stimulation : Sham stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.</description>
          </group>
        </group_list>
        <measure>
          <title>Hallucination Change Score (HCS)</title>
          <description>HCS score assessed after 15 sessions, 16 minutes per session, delivered to both right superior temporal and left superior temporal gyrus sites using either rTMS or sham stimulation. For patients dropping out of the trial prematurely, last-observation-carried-forward data were used for this outcome variable.
HCS was anchored at 0 (corresponding to no AVHs), 10 (no change in hallucination severity) and 20 (AVHs twice as severe as baseline). Lower scores correspond to greater improvement</description>
          <population>Subjects who did not complete the intervention were excluded from the analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.45" spread="3.42"/>
                    <measurement group_id="O2" value="7.51" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hallucination Frequency</title>
        <description>AHRS frequency scale score assessed after 15 sessions, 16 minutes per session, of both right superior temporal and left superior temporal gyrus sites using either rTMS or sham stimulation (3 weeks). For patients dropping out of the trial prematurely, last-observation-carried-forward data were used for this outcome variable. The hallucination frequency range is from 0-9. The scores reported are difference scores, and an improvement is a higher score.
Hallucination frequency is one of the variables incorporated into the AHRS (Auditory Hallucinations Rating Scale). The score is measured as change relative to baseline (i.e., baseline minus endpoint). Larger (positive) scores correspond to greater improvement.</description>
        <time_frame>After 15 sessions of rTMS</time_frame>
        <population>Subjects who did not complete the intervention were excluded from the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Active Arm</title>
            <description>Active 1-hertz Repetitive Transcranial Magnetic Stimulation to Wernicke's area and right homologous area
Active 1-Hertz Repetitive transcranial magnetic stimulation : Active stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>sham rTMS to Wernicke's area and a right homologous area
1-hertz Repetitive Transcranial Magnetic Stimulation : Sham stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hallucination Frequency</title>
          <description>AHRS frequency scale score assessed after 15 sessions, 16 minutes per session, of both right superior temporal and left superior temporal gyrus sites using either rTMS or sham stimulation (3 weeks). For patients dropping out of the trial prematurely, last-observation-carried-forward data were used for this outcome variable. The hallucination frequency range is from 0-9. The scores reported are difference scores, and an improvement is a higher score.
Hallucination frequency is one of the variables incorporated into the AHRS (Auditory Hallucinations Rating Scale). The score is measured as change relative to baseline (i.e., baseline minus endpoint). Larger (positive) scores correspond to greater improvement.</description>
          <population>Subjects who did not complete the intervention were excluded from the analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="1.57"/>
                    <measurement group_id="O2" value="0.30" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Auditory Hall Rating Scale (AHRS) Score</title>
        <description>Total AHRS score assessed after 15 sessions, 16 minutes per session, of both right superior temporal and left superior temporal gyrus sites using either rTMS or sham stimulation (3 weeks). For patients dropping out of the trial prematurely, last-observation-carried-forward data were used for this outcome variable. The score range is from 0-42. This is reported as a difference score and a higher score is an improvement.
Total AHRS score is measured as change relative baseline (i.e., baseline minus endpoint). Larger (positive) scores correspond to greater improvement.</description>
        <time_frame>After 15 sessions of rTMS</time_frame>
        <population>Subjects who did not complete the intervention were excluded from the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Active Arm</title>
            <description>Active 1-hertz Repetitive Transcranial Magnetic Stimulation to Wernicke's area and right homologous area
Active 1-Hertz Repetitive transcranial magnetic stimulation : Active stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>sham rTMS to Wernicke's area and a right homologous area
1-hertz Repetitive Transcranial Magnetic Stimulation : Sham stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Auditory Hall Rating Scale (AHRS) Score</title>
          <description>Total AHRS score assessed after 15 sessions, 16 minutes per session, of both right superior temporal and left superior temporal gyrus sites using either rTMS or sham stimulation (3 weeks). For patients dropping out of the trial prematurely, last-observation-carried-forward data were used for this outcome variable. The score range is from 0-42. This is reported as a difference score and a higher score is an improvement.
Total AHRS score is measured as change relative baseline (i.e., baseline minus endpoint). Larger (positive) scores correspond to greater improvement.</description>
          <population>Subjects who did not complete the intervention were excluded from the analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.48" spread="6.90"/>
                    <measurement group_id="O2" value="3.0" spread="6.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Improvement (CGI)Improvement</title>
        <description>CGI score assessed after 15 sessions, 16 minutes per session, of both right superior temporal and left superior temporal gyrus sites using either rTMS or sham stimulation (3 weeks). For patients dropping out of the trial prematurely, last-observation-carried-forward data were used for this outcome variable. The range for this score is from 1 to 7.
Lower scores correspond to greater improvement</description>
        <time_frame>After 15 sessions of rTMS</time_frame>
        <population>Subjects who did not complete the intervention were excluded from the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Active Arm</title>
            <description>Active 1-hertz Repetitive Transcranial Magnetic Stimulation to Wernicke's area and right homologous area
Active 1-Hertz Repetitive transcranial magnetic stimulation : Active stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>sham rTMS to Wernicke's area and a right homologous area
1-hertz Repetitive Transcranial Magnetic Stimulation : Sham stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Improvement (CGI)Improvement</title>
          <description>CGI score assessed after 15 sessions, 16 minutes per session, of both right superior temporal and left superior temporal gyrus sites using either rTMS or sham stimulation (3 weeks). For patients dropping out of the trial prematurely, last-observation-carried-forward data were used for this outcome variable. The range for this score is from 1 to 7.
Lower scores correspond to greater improvement</description>
          <population>Subjects who did not complete the intervention were excluded from the analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" spread="1.15"/>
                    <measurement group_id="O2" value="3.21" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected throughout the duration of the study, which was approximately 5 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active Arm</title>
          <description>Active 1-hertz Repetitive Transcranial Magnetic Stimulation to Wernicke's area and right homologous area
Active 1-Hertz Repetitive transcranial magnetic stimulation : Active stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Arm</title>
          <description>sham rTMS to Wernicke's area and a right homologous area
1-hertz Repetitive Transcranial Magnetic Stimulation : Sham stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Somatic Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lightheaded/Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Concentration Problems</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening Hallucinations/Audible Thoughts</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ralph Hoffman, MD</name_or_title>
      <organization>Yale University School of Medicine</organization>
      <phone>203-688-9734</phone>
      <email>Ralph.Hoffman@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

